We are passionate to deliver first in class cancer drugs to patients.
To be an R&D oriented pharmaceutical company based in Japan.
We are passionate to deliver first in class cancer drugs to patients from Japan.
Chordia Therapeutics is a biotech company engaged in research and development of novel therapies for cancers.
Professionals who have deep knowledge and experience for oncology area keep on striving toward developing new drugs that will envision the tomorrow of cancer treatment.
In general, it takes a long time for bringing out a new drug to patients.
And we also need the cooperation from collaborators and supporters.
So, the thing that our company always cares about is the speedy research and development which is derived from quick decision-making as an R&D oriented biotech, and the gratitude to our external partners who support our company.
We are advancing drug development quickly and steadily by making the best use of the flexibility of lean organization, broad network of experienced professionals, and the accumulated R&D wisdom.
Out lead asset CLK inhibitor CTX-712, currently under first-stage of clinical trials, has a novel mode of action that kills cancer cells by altering mRNA splicing.
The key to the sustainable growth of biotech companies is the successful development of new drugs, and we aspire to deliver the first in class anti-cancer drug from Japan to patients around the world as soon as possible by leveraging our strengths.